Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10201143 | 0.78 | TSHR (0.50) | TSHRTP53TDP1POLBGAA | |
| SCHEMBL1711012 | 0.78 | TSHR (0.50) | TSHRTP53TDP1POLBGAA | |
| SCHEMBL1107747 | 0.77 | TSHR (0.43) | TSHRTP53TDP1POLBPPARD | |
| Water SCHEMBL4956659 | 0.77 | TP53 (0.41) | TSHRTP53TDP1POLBGAA | |
| SCHEMBL9050380 | 0.75 | POLB (0.46) | TSHRTP53TDP1POLBGAA | |
| SCHEMBL21511095 | 0.75 | HMGCR (0.42) | TSHRTP53TDP1POLBGAA | |
| SCHEMBL9157801 | 0.75 | LAP3 (0.42) | TSHRTP53TDP1POLBGAA | |
| SCHEMBL10911354 | 0.75 | TSHR (0.53) | TSHRTP53TDP1POLBGAA | |
| SCHEMBL11183861 | 0.74 | TSHR (0.46) | TSHRTP53TDP1POLBGAA | |
| SCHEMBL22034596 | 0.74 | TSHR (0.46) | TSHRTP53TDP1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716346-B2 | Alkylating agent combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-8324282-B2 | Alkylating agent combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120065145-A1 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | GERSON STANTON L (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065145-A1 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | GERSON STANTON L (US) | 2012-03-15 | — | — | US | disclosed |
| US-20080058579-A1 | Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors | ANGIOTECH INTERNATIONAL AG (CH) | 2008-03-06 | — | — | US | disclosed |
| US-20080058579-A1 | Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors | ANGIOTECH INTERNATIONAL AG (CH) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065145-A1 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | UNG, TOP2A, OGG1 | TSHR 3648/4885TP53 24/4885TDP1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.